Iodine Status and Characteristics of Papillary Thyroid Cancer

The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Papillary Thyroid Carcinoma Adenocarcinoma Adenocarcinoma, Papillary Carcinoma Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Thyroid Cancer, Papillary Thyroid Diseases Thyroid Neoplasms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age range: 18~65 years old, gender not limited;
Living in the residential area for at least 5 years;
Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer;
Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.

Exclusion criteria

Pathological diagnosis of other types of thyroid cancer;
Diagnosed with other types of cancer;
There are serious comorbidities of the heart, liver, and kidneys;

Treatment and study plan

Iodine excess

Dietary Supplement

Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L

Iodine suitable

Dietary Supplement

Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.

Primary outcomes

Serum and urine iodine levels

Time frame: 1 year from enrollment
TNM staging of papillary thyroid cancer

Time frame: 3 month from enrollment

Study contacts

Contact information is provided by the study sponsor or research team.

Qingling Guo

CONTACT

[email protected]

+86-0531-68776375

Sponsors and collaborators

Lead sponsor

Shandong Provincial Hospital

Other Gov

Registry information

Official study title

A Cross-sectional Study on Iodine Status and Characteristics of Papillary Thyroid Cancer

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Oct 4, 2024
Registry last updated: Oct 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting